Phentolamine: Difference between revisions
No edit summary |
|||
| Line 11: | Line 11: | ||
**Start: within 12h of extravasation | **Start: within 12h of extravasation | ||
*Hypertensive crisis: 5mg IM/IV q2-4h prn | *[[Hypertensive crisis]]: 5mg IM/IV q2-4h prn | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 18: | Line 18: | ||
==Special Populations== | ==Special Populations== | ||
*Pregnancy Risk Factor: C | *[[Drug ratings in pregnancy|Pregnancy Risk]] Factor: C | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
| Line 28: | Line 28: | ||
==Contraindications== | ==Contraindications== | ||
*Hypersensitivity to phentolamine or components | *Hypersensitivity to phentolamine or components | ||
*MI | *[[MI]] | ||
*CAD | *[[CAD]] | ||
*Angina | *Angina | ||
*Caution if PUD | *Caution if PUD | ||
| Line 35: | Line 35: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*MI | *[[MI]] | ||
*stroke | *[[stroke]] | ||
*hypotension, severe | *hypotension, severe | ||
*arrhythmias | *[[arrhythmias]] | ||
*PUD | *PUD | ||
*priapism | *[[priapism]] | ||
===Common=== | ===Common=== | ||
*tachycardia | *tachycardia | ||
*weakness | *[[weakness]] | ||
*dizziness | *[[dizziness]] | ||
*flushing | *flushing | ||
*orthostatic hypotension | *orthostatic hypotension | ||
*nasal congestion | *nasal congestion | ||
*nausea | *[[nausea]] | ||
*vomiting | *[[vomiting]] | ||
*diarrhea | *[[diarrhea]] | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 19 minutes | *Half-life: 19 minutes | ||
| Line 57: | Line 59: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Alpha antagonist | *[[Alpha antagonist]] | ||
==References== | ==References== | ||
<Epocrates, UpToDate> | <Epocrates, UpToDate> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 20:14, 29 September 2016
Administration
- Type: Alpha 1 Blocker; Antidote, Extravasation; Antihypertensive
- Routes of Administration: IV, IM
- Common Trade Names: OraVerse
Adult Dosing
- Pheochromocytomectomy adjunct: 5mg IM/IV q2-4h prn
- Start: 1-2h preop
- Extravasation (norepinephrine-associated): 5-10mg injected into affected area x1
- Start: within 12h of extravasation
- Hypertensive crisis: 5mg IM/IV q2-4h prn
Pediatric Dosing
- Pheochromocytomectomy adjunct: 1mg IM/IV q2-4h prn
- Start: 1-2h preop
Special Populations
- Pregnancy Risk Factor: C
Renal Dosing
- No dosing adjustments
Hepatic Dosing
- No dosing adjustments
Contraindications
Adverse Reactions
Serious
- MI
- stroke
- hypotension, severe
- arrhythmias
- PUD
- priapism
Common
- tachycardia
- weakness
- dizziness
- flushing
- orthostatic hypotension
- nasal congestion
- nausea
- vomiting
- diarrhea
Pharmacology
- Half-life: 19 minutes
- Metabolism: Urine
- Excretion: CYP450
Mechanism of Action
References
<Epocrates, UpToDate>